Retirement Systems of Alabama Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE)

Retirement Systems of Alabama lessened its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 65.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 61,068 shares of the medical instruments supplier's stock after selling 116,501 shares during the period. Retirement Systems of Alabama owned approximately 0.12% of Haemonetics worth $4,768,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Boston Trust Walden Corp boosted its position in Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after buying an additional 106,114 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Haemonetics by 36.1% in the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after purchasing an additional 2,680 shares in the last quarter. KBC Group NV raised its stake in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Haemonetics during the 4th quarter worth $402,000. Finally, Nordea Investment Management AB raised its stake in Haemonetics by 5.5% during the 4th quarter. Nordea Investment Management AB now owns 104,175 shares of the medical instruments supplier's stock worth $8,152,000 after acquiring an additional 5,385 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an "overweight" rating and a $116.00 price target on the stock. Raymond James reiterated a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $101.67.

Haemonetics Stock Performance

NYSE HAE traded up $0.18 during trading on Friday, reaching $62.47. The company's stock had a trading volume of 1,333,274 shares, compared to its average volume of 1,042,682. The firm has a market cap of $3.14 billion, a price-to-earnings ratio of 24.59, a P/E/G ratio of 0.98 and a beta of 0.39. The business's fifty day moving average price is $74.55 and its 200-day moving average price is $77.58. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.